Overview

A Study of Mirikizumab (LY3074828) in Healthy Participants

Status:
Completed
Trial end date:
2018-07-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab